Robert Zemble, MD
Allergy & Immunology · Allentown, PANPI 1124224027
Payments from drug & device makers
Across 457 payments — averaging $30.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Blueprint Medicines Corporation$2K
- CSL Behring$2K
- AstraZeneca$1K
- Sanofi$1K
- GSK$904
- plus $5K from 30 others
What the payments were for
- Consulting fees$1,37510%
- Speaking & faculty fees$2,17416%
- Food & beverage$10,24473%
- Education$1751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $2,071 |
| Blueprint Medicines Corporation | 8 | $2,034 |
| CSL Behring | 65 | $1,816 |
| AstraZeneca | 73 | $1,320 |
| Sanofi | 52 | $1,242 |
| GSK | 42 | $904 |
| Regeneron Healthcare Solutions, Inc. | 14 | $433 |
| Aimmune Therapeutics, Inc. | 5 | $425 |
| Covis Pharma GmbH | 14 | $376 |
| Amgen(2 entities) | 12 | $371 |
| Pfizer | 17 | $369 |
| Kaleo, Inc. | 21 | $322 |
| Biocryst US Sales Co., LLC | 19 | $322 |
| Pharming Healthcare, Inc. | 12 | $314 |
| Boehringer Ingelheim | 8 | $219 |
| Optinose US, Inc. | 11 | $181 |
| Novartis | 8 | $153 |
| Shire North American Group Inc | 6 | $140 |
| Ionis Pharmaceuticals, Inc. | 1 | $125 |
| Genentech USA, Inc. | 8 | $113 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| Sanofi-aventis U.S. LLC | 2 | $95 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $93 |
| Grifols USA, LLC | 5 | $82 |
| Alk-abello, Inc | 5 | $81 |
| Organon | 1 | $44 |
| Merck | 2 | $38 |
| Circassia Inc. | 2 | $35 |
| Greer Laboratories, Inc. | 1 | $25 |
| LEO Pharma Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Bio Products Laboratory USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,967 in reported general payments places this provider in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 38 | $139,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $63,077 |
| Dupixent SyringeDupilumab | 15 | $56,177 |
| XolairOmalizumab | 28 | $39,035 |
| Spiriva RespimatTiotropium Bromide | 22 | $17,766 |
| DuleraMometasone/Formoterol | 32 | $16,932 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $16,438 |
| Arnuity ElliptaFluticasone Furoate | 25 | $14,699 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $14,552 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $9,960 |
| QnaslBeclomethasone Dipropionate | 11 | $8,136 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $8,001 |
| Epinephrine | 34 | $6,543 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $6,102 |
| Azelastine Hcl | 131 | $5,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $904 | $94,214113 claims |
| Boehringer IngelheimSpiriva Respimat | $219 | $17,76622 claims |
| MerckDulera | $38 | $16,93232 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $1,320 | $11,00733 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $99 | $8,13611 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $6,54334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Allentown
- Miae OhAllentown$19K
- Drew WeissmanPhiladelphia$15.3M
- Timothy CraigHershey$2M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Thomas KleinHavertown$222K
- Rahul DattaPhiladelphia$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.